Cycloset Articles
Santarus in-licenses novel type 2 diabetes drug for US market for upfront $5 million and 35%-40% royalties
10 September 2010
Reassuring CV safety from Ph IIIb Cycloset trial
2 July 2007
Showing 1-2 of 2 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
